Therapeutic potential of nitric oxide pathway management in pulmonary arterial hypertension: from nitric oxide to its synthetic analog — Oxacom

Rodnenkov O.V.; Rezukhina E.A.; Zorin A.V.; Lakomkin V.L.; Kapelko V.I.; Gramovich V.V.; Martynyuk T.V.

doi:https://doi.org/10.17116/Cardiobulletin20221704124

Rodnenkov O.V.

Chazov National Medical Research Center of Cardiology

Rezukhina E.A.

Chazov National Medical Research Center of Cardiology

Zorin A.V.

Chazov National Medical Research Center of Cardiology

Lakomkin V.L.

Chazov National Medical Research Center of Cardiology

Kapelko V.I.

Chazov National Medical Research Center of Cardiology

Gramovich V.V.

Chazov National Medical Research Center of Cardiology

Martynyuk T.V.

National Medical Research Center of Cardiology

Scopus AuthorID: 6602715051
ORCID: 0000-0002-9022-8097

Therapeutic potential of nitric oxide pathway management in pulmonary arterial hypertension: from nitric oxide to its synthetic analog — Oxacom

Authors:

Rodnenkov O.V., Rezukhina E.A., Zorin A.V., Lakomkin V.L., Kapelko V.I., Gramovich V.V., Martynyuk T.V.

More about the authors

Journal: Russian Cardiology Bulletin. 2022;17(4): 24‑31

DOI: 10.17116/Cardiobulletin20221704124

Read: 2974 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rodnenkov OV, Rezukhina EA, Zorin AV, Lakomkin VL, Kapelko VI, Gramovich VV, Martynyuk TV. Therapeutic potential of nitric oxide pathway management in pulmonary arterial hypertension: from nitric oxide to its synthetic analog — Oxacom. Russian Cardiology Bulletin. 2022;17(4):24‑31. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20221704124

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Prevention of acute kidney injury in cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):83-89

Gastrointestinal tract protection with nitric oxide in aortic arch surgery: a randomized study. Russian Journal of Anesthesiology and Reanimatology. 2025;(4):13-20

Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95

Antioxidant therapy for the correction of nitrosative stress in inflammatory diseases of the nasal cavity. Russian Rhinology. 2025;(3):191-196

Markers of impaired oocyte maturation in the «poor» ovarian response to controlled ovarian stimulation. Russian Journal of Human Reproduction. 2026;(1):44-56

Abstract:

Modern treatment options forpulmonary arterial hypertension include specific pulmonary vasodilators with various mechanisms of action. Endogenous nitric oxide is essential in regulation of vascular tone, thrombocyte and leucocyte activity, smooth muscle cell and fibroblast proliferation, as well as inflammatory and immune response. Nitric oxide deficiency underlying chronic vasospasm, cell proliferation and intravascular clotting in pulmonary arterial hypertension can be a potential therapeutic target. Endogenous nitric oxide donors are considered an ambitious option in the treatment of pulmonary arterial hypertension This drug is dinitrosyl iron complex with glutathione — Oxacom Intravenous Oxacom therapy for five days may be considered as treatment strategy in patients with pulmonary arterial hypertension and severe clinical aggravation. Therapy contributes to pulmonary artery pressure decrease and hemodynamic stability that reduces the length of hospital-stay.

Keywords:

pulmonary arterial hypertension nitric oxide

dinitrosyl iron complexes

endogenous nitric oxide donors

Oxacom

Authors:

Rodnenkov O.V.

Chazov National Medical Research Center of Cardiology

Rezukhina E.A.

Chazov National Medical Research Center of Cardiology

Zorin A.V.

Chazov National Medical Research Center of Cardiology

Lakomkin V.L.

Chazov National Medical Research Center of Cardiology

Kapelko V.I.

Chazov National Medical Research Center of Cardiology

Gramovich V.V.

Chazov National Medical Research Center of Cardiology

Martynyuk T.V.

National Medical Research Center of Cardiology

Scopus AuthorID: 6602715051
ORCID: 0000-0002-9022-8097

Received:

14.10.2022

Accepted:

27.10.2022

Close metadata

References:

D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Annals of Internal Medicine. 1991;115(5):343-349. https://doi.org/10.7326/0003-4819-115-5-343
Martynyuk TV. Logochnaya gipertenziya: diagnostika i lecheniye. M.: OOO «Meditsinskoye informatsionnoye agentstvo». 2018. (In Russ.).
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal. 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237
Sparacino-Watkins CE, Lai YC, Gladwin MT. Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics. Circulation. 2012;125(23):2824-2826. https://doi.org/10.1161/CIRCULATIONAHA.112.107821
Zuckerbraun BS, George P, Gladwin MT. Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovascular Research. 2011;89(3):542-552. https://doi.org/10.1093/cvr/cvq370
Degoute CS. Controlled hypotension: a guide to drug choice. Drugs. 2007;67(7):1053-1076. https://doi.org/10.2165/00003495-200767070-00007
Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clinics in Chest Medicine. 2007;28(1):43-viii. https://doi.org/10.1016/j.ccm.2006.11.007
Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethwaite PA. Signaling molecules in nonfamilial pulmonary hypertension. The New England Journal of Medicine. 2003;348(6):500-509. https://doi.org/10.1056/NEJMoa021650
Morrell NW, Adnot S, Archer SL, Dupuis J, Lloyd Jones P, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. JACC: Journal of the American College of Cardiology. 2009;54(1 suppl):20-31. https://doi.org/10.1016/j.jacc.2009.04.018
Chazova IE, Martynyuk TV, Valieva ZS, Azizov VA, Barbarash OL, Veselova TN, Galyavich AS, Gorbachevskiy SV, Zelveyan PA, Lazareva IV, Mukarov MA, Nakonechnikov SN, Saidova MA, Sarybayev ASh., Stukalova OV, Shalayev SV, Shmal’ts AA. Eurasian Guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian Heart Journal. 2020;1:78-122. (In Russ.). https://doi.org/10.38109/2225-1685-2020-1-78-122
Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526. https://doi.org/10.1038/327524a0
Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, Wharton J, Malik AB. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. Journal of Clinical Investigation. 2009;119(7):2009-2018. https://doi.org/10.1172/JCI33338
Fagan KA, Tyler RC, Sato K, Fouty BW, Morris KG Jr, Huang PL, McMurtry IF, Rodman DM. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. American Journal of Physiology. 1999;277(3):472-478. https://doi.org/10.1152/ajplung.1999.277.3.L472
Champion HC, Bivalacqua TJ, Greenberg SS, Giles TD, Hyman AL, Kadowitz PJ. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proceedings of the National Academy of Sciences. 2002;99(20):13248-13253. https://doi.org/10.1073/pnas.182225899
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews. 1991;43(2):109-142.
Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340(8823):818-819. https://doi.org/10.1016/0140-6736(92)92686-a
Wennmalm A, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, Westfelt UN, Petersson AS, Waagstein F. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circulation Research. 1993;73(6):1121-1127. https://doi.org/10.1161/01.res.73.6.1121
Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation. 1993;88(6):2884-2887. https://doi.org/10.1161/01.cir.88.6.2884
Högman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet. 1993;341(8861):1664-1665. https://doi.org/10.1016/0140-6736(93)90802-n
Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. European Respiratory Journal. 1998;12(2):265-270. https://doi.org/10.1183/09031936.98.12020265
Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest. 1996;109(6):1545-1549. https://doi.org/10.1378/chest.109.6.1545
Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340(8823):818-819. https://doi.org/10.1016/0140-6736(92)92686-a
Fullerton DA, Jones SD, Jaggers J, Piedalue F, Grover FL, McIntyre RC Jr. Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. The Journal of Thoracic and Cardiovascular Surgery. 1996;111(4):753-763. https://doi.org/10.1016/s0022-5223(96)70335-5
Snell GI, Salamonsen RF, Bergin P, Esmore DS, Khan S, Williams TJ. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. 1995;151(4):1263-1266. https://doi.org/10.1164/ajrccm/151.4.1263
Martynyuk TV. Idiopaticheskaya legochnaya gypertensia: cliniko-patophisiologicheskie osobennosti i vosmozhnosti patogeneticheski obosnovannoi terapii: Dis. ... d-ra med. nauk. M. 2013. (In Russ.).
Moncada S, Palmer RM, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochemical Pharmacology. 1989;38(11):1709-1715. https://doi.org/10.1016/0006-2952(89)90403-6
Lakomkin VL, Vanin AF, Timoshin AA, Kapelko VI, Chazov EI. Long-lasting hypotensive action of stable preparations of dinitrosyl-iron complexes with thiol-containing ligands in conscious normotensive and hypertensive rats. Nitric Oxide. 2007;16(4):413-418. https://doi.org/10.1016/j.niox.2007.03.002
Lakomkin VL, Timoshin AA, Orlova TsR, Gubkina SA, Storozhilova AN, Gvozdik TE, Dobrovolsky AB, Ruuge EK, Vanin AF, Kapelko VI, Lapin BA, Chazov EI. Deystviye dinitrozil’nogo kompleksa zheleza s glutationom — donorom oksida azota — na sistemu krovoobrashcheniya krys i obez’yan s. Kardiologiya. 2009;49(5):53-60. (In Russ.).
Chazov EI, Rodnenkov OV, Zorin AV, Lakomkin VL, Gramovich VV, Vyborov ON, Dragnev AG, Timoshin CA, Buryachkovskaya LI, Abramov AA, Massenko VP, Arzamastsev EV, Kapelko VI, Vanin AF. Hypotensive effect of Oxacom containing a dinitrosyl iron complex with glutathione: animal studies and clinical trials on healthy volunteers. Nitric Oxide. 2012;26(3):148-156. https://doi.org/10.1016/j.niox.2012.01.008
Timoshin AA, Lakomkin VL, Abramov AA, Ruuge EK, Kapel’ko VI, Chazov EI, Vanin AF. The hypotensive effect of the nitric monoxide donor Oxacom at different routs of its administration to experimental animals. European Journal of Pharmacology. 2015;765:525-532. https://doi.org/10.1016/j.ejphar.2015.09.011
Gosteev AI, Zorin AV, Rodnenkov OV, Dragnev AG, Chazov EI. Gemodinamicheskiye effekty sinteticheskogo analoga endogennykh donatorov oksida azota (II) — preparat dinitrozil’nykh kompleksov zheleza u bol’nykh arterial’noy gipertoniyey s neoslozhnennymi gipertonicheskimi krizami. Terapevticheskii arkhiv. 2014;86(9):49-55. (In Russ.). https://ter-arkhiv.ru/0040-3660/article/view/31557
Lakomkin VL, Abramov AA, Lukoshkova EV, Ermishkin VV, Kapelko VI. Deystviye donora nitroksida na sokratitel’nyye svoystva serdtsa ex vivo i in vivo. Rossiiskii fiziologicheskii zhurnal im. I.M. Sechenova. 2017;103(1):71-78. (In Russ.).